RECOVERY & TISSUE REPAIR / MATRIX
Three Peptides, Side by Side
Where the three repair peptides converge, where they diverge, and — most importantly — how far the evidence behind each actually reaches.
The short version
This page lines up BPC-157, TB-500, and GHK-Cu on the dimensions that matter most when reading research peptides: what kind of molecule each one is, where it has been studied most, how strong that evidence is, how it was administered in studies, its regulatory standing, and its single most important caution. The headline is straightforward. All three are studied for recovery and tissue repair, but they are at very different stages: GHK-Cu has the most human (mostly topical) data, BPC-157 has the deepest animal record with three small human pilots, and TB-500's evidence largely belongs to a bigger parent protein. None is an approved medicine, and none is presented here with a human dose.
The comparison matrix
| Dimension | BPC-157 | TB-500 | GHK-Cu |
|---|---|---|---|
| Peptide class | Stable gastric pentadecapeptide (15 aa) | Synthetic actin-binding fragment of thymosin beta-4 (7 aa) | Copper-binding tripeptide / copper tripeptide-1 (3 aa) |
| Most-studied in | Tendon, gut, muscle and nerve repair | Actin biology; cell migration and angiogenesis | Skin regeneration and matrix synthesis |
| Evidence base (model) | Mostly rat; 3 small human pilots [2] | Mostly full-length Tβ4 (animal + 1 human Phase 1) [8][11] | In vitro + small human topical trials [16] |
| Administration studied | IM, intragastric, drinking water, IV pilot [3][5] | IV (full-length Tβ4), IP in animals [9][11] | Topical, ex vivo skin penetration [13][17] |
| Regulatory / WADA status | Not approved; WADA S0 prohibited | Not approved; WADA-prohibited | Cosmetic ingredient (topical); systemic unapproved |
| Key caution | Single-lab, preclinical-heavy record [2] | Fragment vs full-protein identity gap [8] | Poor skin permeability; pigmentation risk [13] |
Peptide class
The three span a size range. BPC-157 is the largest at fifteen amino acids, a stable gastric pentadecapeptide synthesized from a partial sequence of a gastric juice protein. TB-500 is a seven-amino-acid fragment carrying the actin-binding motif of the much larger thymosin beta-4 protein. GHK-Cu is a three-amino-acid copper chelate drawn from the collagen sequence — the smallest and, structurally, the most elemental of the three [12][16].
Most-studied in
Each peptide has a home territory in the research literature. BPC-157's animal record is the broadest, spanning tendon, gut, muscle and nerve [6]. TB-500's research centers on actin biology and the cell migration and angiogenesis that follow from it — studied most through the lens of the parent protein [10]. GHK-Cu is overwhelmingly a skin-and-matrix story: collagen, elastin, and the dermal environment [16]. Together they cover the major structural phases of tissue repair.
Evidence base (model)
This is where the three genuinely separate. GHK-Cu has the most human data, but it is mostly small-scale topical studies plus one 45-patient combination hair-loss trial [15][16]. BPC-157 has a deep, decades-long animal record and three small uncontrolled human pilots [2]. TB-500 is the trickiest: its strongest human data — a Phase 1 IV safety study in 40 volunteers — used full-length thymosin beta-4, not the marketed fragment [8][11].
Administration studied
Routes track the research questions each compound came from. BPC-157 has been studied intramuscularly, intragastrically, in drinking water, and in a tiny intravenous human safety pilot [3][5]. TB-500 / Tβ4 work used intravenous dosing in the human Phase 1 study and intraperitoneal dosing in animals [9][11]. GHK-Cu is studied topically, with ex vivo skin-penetration measurements quantifying how much copper crosses the skin barrier [13][17].
Regulatory / WADA status
None of the three is an FDA- or EMA-approved medicine for systemic use. BPC-157 and TB-500 are both explicitly prohibited in sport by WADA (BPC-157 under the S0 non-approved-substances category) [8]. GHK-Cu is unusual in this group: topical copper tripeptide-1 is a legal, widely sold cosmetic ingredient, while injectable or systemic GHK-Cu is unapproved and research-only [13].
Key caution
Each peptide carries a defining caveat. For BPC-157 it is that the broad, internally consistent signal lives mostly in one research group's rodent work, with only three tiny human pilots [2]. For TB-500 it is the identity gap — the marketed fragment is not the molecule behind most of the efficacy data, plus a theoretical tumor-angiogenesis signal from the parent protein's pro-migratory properties [8][10]. For GHK-Cu it is poor skin permeability and a documented risk of localized hyperpigmentation [13]. Reading them together, the lesson is consistent: promising mechanisms, uneven and often early evidence.